Stockwinners Market Radar for December 05, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. An activist investor is urging department-store chain Kohl's (KSS) to consider a sale of the company or a separation of its e-commerce business, The Wall Street Journal's Cara Lombardo reported. Engine Capital LP wants the retailer to examine the two alternatives to improve its lagging stock price, according to a letter sent to Kohl's board Sunday and viewed by The Wall Street Journal. Engine owns a roughly 1% Kohl's stake. 2. Trump Media & Technology Group Corp. and Digital World Acquisition Corp. (DWAC) announced that the latter has entered into subscription agreements for $1 billion in committed capital to be received upon consummation of their business combination from a diverse group of institutional investors. President Donald Trump, Chairman of TMTG, stated, "$1 billion sends an important message to Big Tech that censorship and political discrimination must end. America is ready for TRUTH Social, a platform that will not discriminate on the basis of political ideology. As our balance sheet expands, TMTG will be in a stronger position to fight back against the tyranny of Big Tech." 3. Wall Street folks used to say Twitter (TWTR) stock would jump when co-founder and CEO Jack Dorsey finally surrendered the reins to a chief executive solely focused on the social-media company, and yet the stock is down about 10% since this past week's news that Twitter technology chief Parag Agrawal would replace Dorsey as CEO, Bill Alpert wrote in this week's edition of Barron's. The selloff gives investors a buying opportunity they haven't seen in years, the author noted. 4. Disney's (DIS) original musical adventure "Encanto" won the post-Thanksgiving weekend domestic box office with another $12.7M in what is always a quiet weekend following the holiday. The movie, which features original songs from Lin-Manuel Miranda, is setting records in parts of Latin America, where it has grossed $5.9M in Colombia. 5. D.R. Horton (DHI), Lennar (LEN), PulteGroup (PHM), Toll Brothers (TOL), Century Communities (CCS), Meritage Homes (MTH), UMH Properties (UMH), Deere (DE), and Nintendo (NTDOY) saw positive mentions in this week's edition of Barron's.

17:12 EST J&J COVID-19 booster shows increase in antibody, T-cell responses - Johnson & Johnson announced preliminary results from an independent study, including a subset of participants from the Janssen-sponsored COV2008 study, conducted by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center, which showed that a booster shot of the Johnson & Johnson COVID-19 vaccine, administered at six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. These results demonstrate the potential benefits of heterologous boosting. The article describing these results have been posted on medRxiv. These Phase 2 data are reinforced by preliminary results from the U.K. COV-BOOST clinical study published in The Lancet, which demonstrated that following primary vaccination with two doses of either BNT162b2 or ChAdOx1 nCov-19, a booster dose of the Johnson & Johnson COVID-19 vaccine increased both antibody and T-cell responses. In this preliminary study, boosting with the Johnson & Johnson COVID-19 vaccine after a primary vaccine regimen of BNT162b2 appears to lead to a greater increase in CD8+ T-cell responses than boosting with BNT162b2. These T-cell response data suggest differences between immune responses following homologous boosting with BNT162b2, and mix-and-match boosting with the Johnson & Johnson COVID-19 vaccine following a primary regimen of BNT162b2. Both the Johnson & Johnson COVID-19 vaccine and BNT162b2 as boosters led to similar neutralizing and binding antibody levels against the original SARS-CoV-2 strain, as well as the Delta and Beta variants, four weeks following the boost. However, after a mix-and-match booster dose of the Johnson & Johnson COVID-19 vaccine, antibodies continued to increase for at least four weeks whereas in individuals who received a homologous boost with the BNT162b2 vaccine, antibodies declined from week two to week four post-boost. For this study, a specimen biorepository at Beth Israel Deaconess Medical Center obtained samples from individuals who received the BNT162b2 vaccine. Participants either continued follow-up in the biorepository and were boosted with 30 ug BNT162b2 or were enrolled in the COV2008 study and were boosted with 5, 2.5, or 1x1010 vp of the Johnson & Johnson COVID-19 vaccine. The COV2008 study is a Johnson & Johnson sponsored, ongoing, blinded Phase 2 clinical trial to evaluate its COVID-19 vaccine as a booster in adults 18 years of age and older.